Background {#Sec1}
==========

Foot ulceration is a worldwide public health concern that causes significant morbidity \[[@CR1]--[@CR5]\]. Its incidence appears to be accelerated by concurrent diabetes and other common illnesses, such as peripheral arterial disease \[[@CR3], [@CR4], [@CR6]\]. Ulcers frequently become infected, limit mobility, and may lead to amputation and mortality \[[@CR3], [@CR4]\]. However, when modifiable risk factors are identified and managed early, such complications are often preventable \[[@CR7], [@CR8]\].

Although risk factors for ulceration have been extensively studied in patients with diabetes \[[@CR9], [@CR10]\], there is surprisingly limited high-quality evidence in the dialysis population, despite an estimated 14% prevalence \[[@CR11]\]. Both foot salvage and survival rates are poor in these patients; only half survive 12 months after amputation \[[@CR3], [@CR4], [@CR12]\]. We previously reported in a systematic review of existing studies that the strongest risk factors for ulceration in dialysis patients include previous ulceration or amputation, peripheral neuropathy, diabetes and macrovascular disease \[[@CR11]\]. However, studies in our review did not provide high-level evidence because of small sample sizes, inadequate appraisal of risk factors or comorbidities, and most were cross-sectional or retrospective. This study aimed to address these deficiencies.

Methods {#Sec2}
=======

Detailed methods have been described elsewhere \[[@CR13], [@CR14]\]. This study was approved by the relevant institutional ethics committees and all participants gave written informed consent \[[@CR13]\].

Participants {#Sec3}
------------

This multi-center prospective cohort study recruited adults with end-stage renal disease (ESRD) from 13 satellite and home-therapy dialysis units in Melbourne, Australia from January 2014 to December 2015 (Fig. [1](#Fig1){ref-type="fig"} and Table [1](#Tab1){ref-type="table"}). Participants were eligible if they had ESRD and were clinically stable on dialysis (hemodialysis or peritoneal dialysis), aged 18 years or over, and able to provide informed consent (i.e. cognitively aware). Participants were excluded if they had insufficient English language skills to provide informed consent or follow instructions. Fig. 1Diagram of participant flow and study outcomes Table 1Participant characteristics according to foot ulceration status at follow-upTotal (*N* = 450)Foot ulcerationYes (*n* = 81)No (*n* = 369)*P*-value\*Time to follow-up, mean (SD), days366 (8)366 (7)366 (9)0.48Age, mean (SD), years68 (13)69 (10)67 (14)0.33Male sex, n (%)291 (65)56 (69)235 (64)0.42BMI, mean (SD), kg/m^2^28.2 (6.6)29.9 (7.0)27.8 (6.4)0.01**\***Current smoking, n (%)54 (12)9 (11)45 (12)0.93Cause of ESRD Diabetes mellitus, n (%)180 (40)53 (65)127 (34)\< 0.001**\*** Hypertension, n (%)28 (6)4 (5)24 (7)0.78 Glomerulonephritis, n (%)97 (22)11 (14)86 (23)0.08 Polycystic kidney disease, n (%)22 (5)4 (5)18 (5)\> 0.99 Reflux, n (%)19 (4)1 (1)18 (5)0.24 Renovascular disease, n (%)10 (2)3 (4)7 (2)0.56 Vasculitis, n (%)9 (2)1 (1)8 (2)0.92 Unknown, n (%)15 (3)0 (0)15 (4)0.13 Other, n (%)70 (16)4 (5)66 (18)0.006**\***Dialysis treatment Hemodialysis, n (%)423 (94)79 (98)344 (93)0.85 Peritoneal dialysis  CAPD, n (%)9 (2)1 (1)8 (2)0.92  APD, n (%)18 (4)1 (1)17 (5)\> 0.99Dialysis duration, median (IQR), months36.9 (16.6 to 70.1)41.3 (19.7 to 82.1)36.4 (14.7 to 67.4)0.28Diabetes, n (%)226 (50)58 (72)168 (46)\< 0.001**\*** Type 1, n (%)13 (6)6 (7)7 (2)0.16 Type 2, n (%)213 (94)52 (64)161 (44)0.16Diabetes duration, mean (SD), months256.3 (152.6)311.7 (157.2)237.1 (146.6)0.002**\***Known peripheral neuropathy, n (%)70 (16)31 (38)39 (11)\< 0.001**\***Known peripheral arterial disease, n (%)79 (18)36 (44)43 (12)\< 0.001**\***Hypertension, n (%)^a^360 (80)66 (82)294 (80)0.83Dyslipidemia, n (%)301 (67)64 (79)237 (64)0.02**\***Ischemic heart disease, n (%)263 (58)58 (72)205 (56)0.01**\***Cerebrovascular disease, n (%)104 (23)31 (38)73 (20)0.001**\***CRP, median (IQR), mg/L^b^7.33 (2.83 to 19.67)10.33 (4.65 to 24.38)6.67 (2.67 to 18.75)0.03Serum albumin, mean (SD), g/L33.7 (3.9)32.8 (4.9)33.9 (3.7)0.06Total calcium, mean (SD), mmol/L2.20 (0.14)2.20 (0.15)2.20 (0.13)0.86Serum phosphate, mean (SD), mmol/L1.55 (0.38)1.60 (0.44)1.54 (0.37)0.27PTH, median (IQR), pmol/L29.58 (18.04 to 45.84)27.53 (21.17 to 45.97)29.83 (16.93 to 45.65)0.46HbA1c, mean (SD), %^b^6.14 (1.31)6.65 (1.35)6.02 (1.28)\< 0.001**\***Hemoglobin, median (IQR), g/L111.3 (102.9 to 117.7)112.7 (102.8 to 120.2)111.0 (102.8 to 117.3)0.30Previous foot ulceration, n (%)97 (22)45 (56)52 (14)\< 0.001**\***Baseline foot ulceration, n (%)45 (10)36 (44)9 (2)\< 0.001**\***Baseline amputation, n (%)46 (10)30 (37)16 (4)\< 0.001**\***Data are n (%), unless otherwise specified. Percentages may not add up to 100%, as they are rounded to the nearest percentThe complete dataset of participant characteristics can be found in Additional file [1](#MOESM1){ref-type="media"}*SD* Standard deviation, *BMI* Body mass index, *ESRD* End-stage renal disease, *CAPD* Continuous ambulatory peritoneal dialysis, *APD* Automated peritoneal dialysis, *IQR* Interquartile range, *CRP* C-reactive protein, *PTH* Parathyroid hormone, *HbA1c* Glycated hemoglobinSI conversion factor: To convert CRP to nanomoles per liter, multiply by 9.524. To convert PTH to nanograms per liter, multiply by 9.4. To convert HbA1c to proportion of total hemoglobin, multiply by 0.01\*Significant difference between 'foot ulceration' and 'no foot ulceration' groups, *p* \< 0.05^a^Requiring medication^b^Maximum missing data were for glycated hemoglobin (HbA1c) involving 39 participants overall (8.7%). Missing data were for glycated hemoglobin (*n* = 39) and C-reactive protein (*n* = 3)

Data collection {#Sec4}
---------------

One examiner (M.R.K.) collected baseline (participant interview, medical record review, health-status and foot examination) and 12-month data (primary and secondary outcomes). Twenty participants were also included in a reliability study to evaluate examiner reliability of the assessment tools \[[@CR13], [@CR14]\]. In brief, there was strong intra-examiner reliability for the foot assessments. For continuous data, intra-class correlation coefficients ranged from 0.87 to 0.99. For dichotomous data, all weighted kappa values equalled 1.00 with the absolute percentage agreement ranging from 95 to 100% \[[@CR14]\].

Primary outcome {#Sec5}
---------------

The primary outcome was the development of a foot ulcer, which was verified by reviewing medical records \[[@CR13]\]. Foot ulcers were documented as 'new' or 'reoccurring', however both were classified and recorded as the primary outcome in this study. *New ulcers* were defined as an ulcer that occurred for the first time during the study period, or, if a participant had an ulcer at baseline, a new ulcer at a different site on the same or contralateral foot during the study period. *Reoccurring ulcers* were defined as a foot ulcer present at baseline that healed and re-ulcerated at the same site during the study.

Secondary outcomes {#Sec6}
------------------

Secondary outcomes included: number and time to onset of new foot ulcers and new lower extremity amputations; episodes of foot or lower limb infection, osteomyelitis, and foot-related hospitalizations; lower extremity revascularization procedures; new podiatry interventions; kidney transplantation; and mortality \[[@CR13]\]. Time to onset was defined as the 'number of days between baseline and the development of a new foot ulcer' \[[@CR13]\]. Secondary outcomes were verified by reviewing medical records.

Sample size {#Sec7}
-----------

Four hundred and fifty participants were recruited with a pre-specified sample size \[[@CR13]\].

Statistical analysis {#Sec8}
--------------------

Primary and secondary outcome data were calculated and expressed as mean (standard deviation, SD) or median (interquartile range, IQR). Continuous data were checked for normality. To explore between-group differences, independent samples *t*-tests, Mann-Whitney *U* tests and/or Chi-square tests were calculated depending on data type. Unadjusted foot ulcer incidence rates were calculated for number of events per 1000 person-years.

Univariate and multivariate relative risks were estimated by Cox proportional hazard modelling for new cases only (i.e. excluded participants with a baseline ulcer) and were adjusted for peripheral neuropathy, previous foot ulceration and cerebrovascular disease. We performed stratified analyses to assess whether the association between diabetes and risk of ulceration varied. The Nelson-Aalen cumulative hazard estimate and the Kaplan Meier survival estimates were calculated. Univariate modelling included risk factors with *p* \< 0.2. We performed a step-wise modelling approach where models were built to exclude *p* \> 0.1 and include if *p* \< 0.05. The models were checked proportionally with time dependence and Schoenfeld scaled residuals. Goodness of fit was examined with Cox-Snell residuals.

Multinomial logistic regression was used to relate a three-category outcome to screened variables at baseline. Categories included: (i) no development of foot ulceration (no previous or baseline ulceration, and did not develop ulceration) \[reference category\], (ii) development of foot ulceration (no previous or baseline ulceration, but developed ulceration), and (iii) development of foot ulceration (previous and/or baseline ulceration, and developed ulceration). The multinomial regression model resulted in two sets of odds ratios (OR) for each risk factor and each level of the outcome. Models were adjusted for age, male sex, living alone, podiatry attendance. Risk estimates were presented as relative risk (RR) or hazard ratios (HR) with 95% confidence intervals (CIs). The threshold for statistical significance was set at *p* \< 0.05 \[[@CR13]\].

We stratified the data by diabetes status to identify possible effect modification. Where indicated, models with interaction terms between diabetes status and other risk factors were considered statistically significant with a *p*-value of \> 0.1 to avoid missing any important interactions.

IBM SPSS version 23.0 (IBM Corp, Somers, NY, USA) and STATA 13.1 Data Analysis and Statistical Software (StataCorp LP, Texas, USA) were used for statistical analysis.

Results {#Sec9}
=======

Participant characteristics {#Sec10}
---------------------------

Mean (SD) follow-up was 366 (8) days. Table [1](#Tab1){ref-type="table"} and Additional file [1](#MOESM1){ref-type="media"} provide the participant characteristics according to ulceration status at follow-up. Prevalence data for foot complications have been reported elsewhere \[[@CR14]\]. Frequency data for primary and secondary outcomes are shown in Table [2](#Tab2){ref-type="table"} and Additional file [2](#MOESM2){ref-type="media"}. Foot examination, foot-health care behaviors and podiatry attendance according to ulceration status at follow-up are presented in Additional file [3](#MOESM3){ref-type="media"}. Table 2Primary and secondary outcomes according to foot ulceration status at follow-upTotal (*N* = 450)Foot ulcerationYes (*n* = 81)No (*n* = 369)*P*-value\*Foot ulceration, n (%)^a^81 (18)81 (100)N/AN/ATotal number of new foot ulcers^b^211211 New, total no. (%)200 (95)200 (95) Reoccurring, total no. (%)11 (5)11 (5)Time to onset of first foot ulcer, mean (SD), days164 (127)164 (127)New lower extremity amputation, n (%)12 (3)12 (15)0 (0) Minor, n (%)12 (3)12 (15)0 (0) Major, n (%)2 (0.4)2 (3)0 (0)Total number of amputations^b^2020N/AMinor, total no. (%)^c^18 (90)18 (90)Major, total no. (%)^d^2 (10)2 (10)Reason for amputation Infected foot ulcer, total no. (%)8 (40)8 (40) PAD/gangrene, total no. (%)9 (45)9 (45) Osteomyelitis, total no. (%)3 (15)3 (15)Time to first amputation, mean (SD), days202 (104)202 (104)Episodes of lower limb/foot infection, n (%)96 (21)53 (65)43 (12)\< 0.001**\***Total number of infections^b^18213052\< 0.001\*Episodes of osteomyelitis, n (%)24 (5)23 (28)1 (0.3)\< 0.001\*Foot-related hospitalizations, n (%)42 (9)35 (43)7 (2)\< 0.001\*Total number of hospitalizations^b^746680.08Reason for hospital admission Infected foot ulcer, n (%)17 (4)16 (20)1 (0.3)0.10 Lower extremity amputation, n (%)5 (1)4 (5)1 (0.3)\> 0.99 Lower extremity revascularization procedure, n (%)8 (2)4 (5)4 (1)0.09 PAD/gangrene, n (%)9 (2)8 (10)1 (0.3)0.69 Cellulitis, n (%)7 (2)4 (5)3 (0.8)0.31 Osteomyelitis, n (%)4 (0.9)4 (5)0 (0)0.65 Other, n (%)10 (2)8 (10)2 (0.5)\> 0.99Length of stay, mean (SD), days25 (23)28 (23)10 (9)0.002**\***Lower extremity revascularization procedure, n (%)24 (5)20 (25)4 (1)\< 0.001**\***Total number of lower extremity revascularization procedures^b^423750.18 Angioplasty, total no. (%)34 (81)30 (81)4 (80)Omitted Bypass, total no. (%)2 (5)2 (5)0 (0)Omitted Stent, total no. (%)6 (14)5 (14)1 (20)OmittedNew podiatry attendance, n (%)38 (8)13 (16)25 (7)\< 0.001**\***Kidney transplantation, n (%)30 (7)5 (6)25 (7)\> 0.99Time to transplant, mean (SD), days195 (115)191 (89)196 (121)0.91All-cause mortality, n (%)52 (12)14 (17)38 (10)0.11 Foot-related death, n (%)^e^6 (12)5 (36)1 (3)0.005**\***  Sepsis due to infected foot ulcer, n (%)^e^5 (10)5 (36)0 (0)0.001**\***  Complications of PAD, n (%)^e^1 (2)0 (0)1 (3)\> 0.99 Other causes of death, n (%)^e^46 (88)9 (64)37 (97)0.005**\***  Myocardial infarction, n (%)^e^10 (19)3 (21)7 (18)\> 0.99  Withdrawal from dialysis, n (%)^e^8 (15)2 (14)6 (16)\> 0.99  Pneumonia, n (%)^e^8 (15)0 (0)8 (21)0.15  Sepsis (not foot-related), n (%)^e^5 (10)0 (0)5 (13)0.37  Intestinal necrosis, n (%)^e^3 (6)1 (7)2 (5)\> 0.99  ESRD, n (%)^e^3 (6)1 (7)2 (5)\> 0.99  Other, n (%)^e^9 (17)2 (14)7 (18)\> 0.99Time to death, mean (SD), days193 (115)192 (112)194 (118)0.96Data are n (%), unless otherwise specified. Percentages may not add up to 100%, as they are rounded to the nearest percentThe complete dataset of primary and secondary outcomes can be found in Additional file [2](#MOESM2){ref-type="media"}*SD* Standard deviation, *PAD* Peripheral arterial disease, *ESRD* End-stage renal disease\*Significant difference between 'foot ulceration' and 'no foot ulceration' groups, *p* \< 0.05^a^Includes new and reoccurring foot ulcers. Reoccurring ulcers were in 9 participants (2.0%)^b^Total number^c^Minor amputations included: 10 single toe, 4 multiple toes, 1 partial toe, 1 single toe and metatarsal, and 2 transmetatarsal amputations^d^Major amputations included: 2 below knee amputations^e^Percentage calculated from all-cause mortality data

Primary outcome {#Sec11}
---------------

New foot ulceration was identified in 81 (18.0%) participants (Fig. [1](#Fig1){ref-type="fig"}). Of these, new foot ulceration occurred in 67/398 (16.8%) participants who were alive at the 12-month follow-up and 14/52 (26.9%) participants who died during the study period (new foot ulceration in 5/6 with foot-related death and 9/46 with other causes of death). Mean time to onset of first ulcer was 164 (SD, 127) days. Annual incidence of ulceration was 122 per 1000 person-years with 211 new ulcers in total (200 new and 11 reoccurring), the majority 128/211 (60.7%) were located on the toes (Table [3](#Tab3){ref-type="table"}). Table 3Characteristics of foot ulcers and amputationsFoot ulcerationAmputationTotal (*n* = 81)Left (*n* = 48)Right (*n* = 55)Total (*n* = 12)Left (*n* = 8)Right (*n* = 5)Foot ulcers, total no. (%)211 (100)103 (49)108 (51)Amputations, total no. (%)20 (100)11 (55)9 (45) New, total no. (%)200 (95)97 (95)103 (95) Minor, total no. (%)^a^18 (90)11 (100)7 (78) Reoccurring, total no. (%)11 (5)6 (6)5 (2) Major, total no. (%)^a^2 (10)0 (0)2 (22)Foot ulcers per participantAmputations per participant Mean (SD), range2.6 (2.0), 1 to 112.0 (1.2), 1 to 51.9 (1.2), 1 to 6 Mean (SD), range1.7 (0.8), 1 to 30.9 (0.9), 0 to 30.8 (1.1), 0 to 3 Median (IQR)2 (1 to 4)2 (1 to 3)1 (1 to 2) Median (IQR)1.5 (1 to 2)1.0 (0 to 1)0 (0 to 1.3)Location^b^Location Toes (dorsal, lateral or medial), total no. (%)124 (59)65 (63)59 (55) Single toe, total no. (%)10 (50)7 (64)3 (33) Plantar toes, forefoot, midfoot, total no. (%)41 (19)18 (18)23 (21) Multiple toes, total no. (%)4 (20)2 (18)2 (22) Dorsal foot, total no. (%)14 (7)7 (7)7 (7) Partial toe, total no. (%)1 (5)1 (9)0 (0) Heel, total no. (%)32 (15)13 (13)19 (18) Metatarsal + single toe, total no. (%)1 (5)0 (0)1 (11) Transmetatarsal, total no. (%)2 (10)1 (9)1 (11) Below knee amputation, total no. (%)2 (10)0 (0)2 (22)TypeReason for amputation Neuropathic, total no. (%)23 (11)16 (16)7 (7) Infected foot ulcer, total no. (%)8 (40)4 (36)4 (44) Neuro-ischemic, total no. (%)129 (61)61 (59)68 (63) PAD/gangrene, total no. (%)9 (45)5 (46)4 (44) Ischemic, total no. (%)10 (5)5 (5)5 (5) Osteomyelitis, total no. (%)3 (15)2 (18)1 (11) Pressure injury, total no. (%)32 (15)13 (13)19 (18) Other/unknown, total no. (%)17 (8)8 (8)9 (8)Time to first foot ulcer, mean (SD), days164 (127)178 (124)182 (125)Time to first amputation, mean (SD), days202 (104)253 (90)130 (79)Data are total number of foot ulcers or amputations (%), unless otherwise specified. Percentages may not add up to 100%, as they are rounded to the nearest percent*SD* Standard deviation, *IQR* Interquartile range, *PAD* Peripheral arterial disease^a^Amputations were classified as 'minor' if below the ankle, or 'major' if above the ankle^b^Majority of foot ulcers 128/211 (60.7%) were located on the toes (dorsal, lateral, medial or plantar aspects)

Secondary outcomes {#Sec12}
------------------

Among the 450 participants, 12 (2.7%) had at least one new amputation, with 20 amputations in total (18 minor and 2 major). The majority occurred due to peripheral arterial disease and/or gangrene (45.0%), infected foot ulcers (40.0%), and osteomyelitis (15.0%) (Tables [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"}).

Over 20% of participants (*n* = 96) had ≥1 foot or leg infection (182 episodes in total), including cellulitis (10.9%) and local wound infection (8.2%). Osteomyelitis occurred in 24 (5.3%), and 42 (9.3%) were admitted to hospital at least once for foot-related issues (74 admissions in total). The mean length of stay was 25 (SD, 23) days, with foot ulcer infection (28.4%) the most common reason for hospitalization. Revascularization procedures of the lower extremity (42 procedures in total) were performed on 24 (5.3%), the majority being angioplasties (81.0%) (Table [2](#Tab2){ref-type="table"}).

Fifty-two (11.6%) died, the most common causes being myocardial infarction (23.1%), withdrawal from dialysis (15.4%), and pneumonia (15.4%). Specifically, six participants died from foot-related consequences: five from systemic sepsis secondary to an infected foot ulcer, and one from complications of peripheral arterial disease (Table [2](#Tab2){ref-type="table"}).

Risk factors for foot ulceration {#Sec13}
--------------------------------

Additional file [4](#MOESM4){ref-type="media"} presents the risk factors that were significant in the univariate Cox proportional hazard model for foot ulceration. Risk factors with greatest hazard were previous lower extremity amputation (HR 6.52, 95% CI 2.83 to 14.99) and peripheral neuropathy (HR 4.14, 95% CI 1.99 to 8.61) (Additional file [5](#MOESM5){ref-type="media"} -- Kaplan-Meier survival estimates). Diabetes mellitus was not found to be a significant risk factor (HR 1.24, 95% CI 0.66 to 2.33), however stratification by diabetes status indicated modification of effects of other risk factors.

A subset of these risk factors were selected for inclusion in the multivariate Cox proportional hazard model based on their contribution to the maximum log partial likelihood and the statistical significance of the risk factor at *p* \< 0.05 and exclusion at *p* \> 0.1. In a multivariate analysis, peripheral neuropathy (HR 3.02, 95% CI 1.48 to 6.15, *p* = 0.002), previous foot ulceration (HR 2.86, 95% CI 1.53 to 5.34, *p* = 0.001) and cerebrovascular disease (HR 1.82, 95% CI 0.98 to 3.36, *p* = 0.057) remained as significant risk factors (Table [4](#Tab4){ref-type="table"}). Table 4Multivariate Cox proportional hazard model of risk factors for foot ulcerationRisk factorHR (95% CI)*P*-value\*Peripheral neuropathy3.02 (1.48 to 6.15)0.002\*Previous foot ulceration2.86 (1.53 to 5.34)0.001\*Cerebrovascular disease1.82 (0.98 to 3.36)0.06Analysis only includes participants without an ulcer at baseline*HR* Hazard ratio, *CI* Confidence interval\*Significant risk factor, *p* \< 0.05

Results of multinomial regression analyses are shown in Table [5](#Tab5){ref-type="table"}. In those *without* a history of ulceration, nail pathology (RR 3.85, 95% CI 1.08 to 13.75) and neuropathy (RR 2.66, 95% CI 1.04 to 6.82) were significant risk factors. In those *with* history of ulceration, neuropathy (RR 11.23, 95% CI 3.16 to 39.87), peripheral arterial disease (RR 7.15, 95% CI 2.24 to 22.82), and cerebrovascular disease (RR 2.08, 95% CI 1.04 to 4.16) were significant. Table 5Multinomial regression analysis of risk factors for foot ulcerationPrimary outcomeCategoryNRisk factorRR (95% CI)*P*-value\*†No development of foot ulceration(i) No previous or baseline ulceration, and did not develop ulceration during study period369Reference CategoryDevelopment of foot ulceration^a^(ii) No previous or baseline ulceration, but developed ulceration during study period27Diabetes mellitus0.68 (0.28 to 1.63)0.39Neuropathy2.66 (1.04 to 6.82)0.04\*Peripheral arterial disease0.58 (0.24 to 1.41)0.23Cerebrovascular disease1.37 (0.54 to 3.50)0.51Nail pathology3.85 (1.08 to 13.75)0.04\*(iii) Previous and/or baseline ulceration, and developed ulceration during study period54Diabetes mellitus1.84 (0.75 to 4.48)0.18Neuropathy11.23 (3.16 to 39.87)\< 0.001†Peripheral arterial disease7.15 (2.24 to 22.82)0.001†Cerebrovascular disease2.08 (1.04 to 4.16)0.04\*Nail pathology1.02 (0.43 to 2.45)0.95Adjusted for age, sex, living alone, podiatry attendance and diabetes*RR* Relative risk, *CI* Confidence interval\*Significant risk factor, *p* \< 0.05†Significant risk factor, *p* \< 0.01^a^Includes new and reoccuring foot ulcers

Discussion {#Sec14}
==========

Being alive, ulcer free and with limbs intact are important patient-related outcomes \[[@CR15]\]. This study identified 211 foot ulcers in 450 stable dialysis patients over 12 months. Twelve participants required amputation and 6 participants died from foot-related complications. There were 74 hospital admissions (average of 25 days/admission) and 24 cases of osteomyelitis. Overall, in our sample of 450 participants, nearly a third (26.4%) had either died, developed an ulcer or had a lower limb amputation at 12 months.

Peripheral neuropathy and previous foot ulceration were found to be major risk factors for the development of foot ulceration, which is consistent with other studies \[[@CR14], [@CR16]--[@CR19]\] and our previous meta-analysis \[[@CR11]\]. These findings add to existing retrospective and cross-sectional studies by demonstrating a temporal association between these risk factors and foot ulceration. It is notable that peripheral neuropathy increased the risk of ulceration 3-fold. The sensory, motor and autonomic components of diabetic and/or uremic polyneuropathy often result in unnoticed injuries, muscle atrophy with associated foot deformity, and drying/fissuring of the skin \[[@CR20], [@CR21]\]. It is also notable that those with a history of ulceration were nearly 3-fold more likely to develop foot ulceration, as these patients often have the same risk factors that contributed to the original ulcer.

Although cerebrovascular disease had borderline significance (*p* = 0.06) in the multivariate analysis (confounded by neuropathy and previous ulceration), it was found to be a risk factor for ulceration in the multinomial analysis, specifically for those *with* a history of ulceration. A previous study \[[@CR22]\] supports our finding that cerebrovascular disease may be an important risk factor for ulceration in dialysis patients (OR 2.78, 95% CI 1.02 to 7.62). This may be explained by a high prevalence of underlying atherosclerosis and microangiopathy with an associated reduction in cognition or functional status in dialysis patients with cerebrovascular disease \[[@CR22]\]. This in turn may affect adherence to foot care or attendance to podiatry services. In addition, cerebrovascular disease may increase risk of falls and subsequent foot trauma or injury \[[@CR20]\], so its relevance should not be discounted.

There were three additional important findings from our study. First, multinomial regression found that risk factors differ between those with and without prior ulceration. In those *without* a history of ulceration, nail pathology (RR 3.85) and neuropathy (RR 2.66) were risk factors. Whereas, in those *with* a history of ulceration, neuropathy (RR 11.23), peripheral arterial disease (RR 7.15), and cerebrovascular disease (RR 2.08) were dominant risk factors. However, these findings should be interpreted with caution as only 27 cases without past or baseline ulceration developed a foot ulcer during the study period.

Second, diabetes was not found to be a significant risk factor in our multivariate Cox proportional hazard or multinomial regression analysis, which differs from the results of our previous meta-analysis \[[@CR11]\], where diabetes increased the risk of ulceration by 3.76-fold. This discrepancy may be explained by some of the limitations of the systematic review including: small sample sizes, unavailability of raw data, unexplained between-study heterogeneity, and a greater risk of confounding from measured and unmeasured factors (unadjusted risk factor data were sourced from non-randomized studies) \[[@CR11]\]. The finding that diabetes was not a significant risk factor for ulceration in the current study is, however, consistent with our previous work \[[@CR14]\] (OR 2.13, 95% CI 0.71 to 6.36), and suggests that much of the effect of diabetes on the risk of foot ulceration is mediated by coexisting neuropathy and/or peripheral arterial disease. In addition, diabetes confounded and was an effect modifier for both neuropathy and peripheral arterial disease. These results are also similar to our previous cross-sectional study \[[@CR14]\], where diabetes was found to be a strong effect modifier (although particularly in men) for inter-related risk factors. Therefore, its existence in the dialysis population remains relevant and should not be discounted when establishing risk. Importantly, the study found a high rate of peripheral sensory neuropathy in participants with (66%) and without diabetes (35%), and that neuropathy was a strong risk factor for ulceration. As previously reported \[[@CR14]\], 70 participants (15.6%) had peripheral neuropathy documented in their medical records prior to the baseline assessment. Remarkably, half the cohort (50.7%) were found to have peripheral sensory neuropathy on examination. This finding highlights that uremic neuropathy may be underdiagnosed, and provides further impetus for regular foot examination, where peripheral neuropathy is assessed, in the dialysis population \[[@CR14]\].

Third, our study highlights a high annual incidence of foot ulceration in the dialysis population (122 events per 1000 person-years). Significantly, this is greater than two previous retrospective studies \[[@CR2], [@CR16]\], which may reflect issues of data recall and missing data in those studies. In addition, we found high rates of new lower extremity amputations, episodes of infection, revascularization procedures, and foot-related hospital admissions, which are generally comparable to previous studies \[[@CR2], [@CR3]\]. A Cox proportional hazard analysis for amputation (our secondary outcome) was not performed due to insufficient numbers (*n* = 12), most likely due to the limited follow-up time.

There are several potential limitations of this study. First, we did not exclude participants with a history of ulceration, as we wanted to establish the prevalence of previous/current ulceration, as well as the incidence of new ulceration. This was addressed by excluding those with a baseline ulcer in the Cox proportional hazards analysis, and the multinomial analysis compared participants according to ulceration status (previous/current) at baseline. Second, despite our best efforts to recruit a representative sample of dialysis patients, our cohort was largely from satellite (hospital-based) dialysis units, with the majority undertaking hemodialysis. Third, recall bias may have been present (e.g. participants self-reported new foot ulcers), however medical records were reviewed and health care providers were contacted if clarification was needed, so this was unlikely. Fourth, it was not possible to distinguish between different subtypes of peripheral neuropathy or other neuropathic conditions (e.g. diabetic amyotrophy) as non-invasive neurological assessments were used. This study focused on identifying the presence/extent of peripheral 'sensory' neuropathy, which from a clinical perspective, is considered the most important issue in establishing foot ulcer risk. Fifth, it is uncertain whether the presence of peripheral arterial disease may have been overestimated, particularly for toe- and ankle-brachial pressure indices, as previous small studies have indicated that cutaneous microcirculation may be affected during dialysis \[[@CR23], [@CR24]\]. To address this, foot assessments were conducted on participants prior to dialysis or on a non-dialysis day \[[@CR13]\], however arterial assessments were mostly performed during dialysis treatment. In addition, footwear assessment was performed on shoes worn by participants at their baseline appointment, which may not have been representative. Finally, it was not possible to control for all potential confounding interventions that participants may have received from other sources.

There are several strengths of this study. It was adequately powered, and the large sample size, multi-center recruitment and inclusion of a full range of risk factors allow the findings to be generalized to clinical practice. No participants were lost to follow-up, so a complete data set was analyzed. Finally, the prospective study design has established, for the first time, a temporal association between screened risk factors and an increase in foot ulceration in dialysis patients.

Our study highlights a clear need for foot care provision to dialysis patients, either with or without the presence of diabetes. Given that those with peripheral neuropathy and/or previous ulceration have an approximately 3-fold risk of new ulceration, dialysis patients may benefit from strategies to prevent foot complications, such as regular foot screening and early intervention. Further research is needed to evaluate the effectiveness of these strategies.

Conclusions {#Sec15}
===========

This study is the first to identify longitudinal risk estimates for foot ulceration in a large dialysis cohort. Risk factors differ between those with and without a history of ulceration, however adults on dialysis with peripheral neuropathy and previous foot ulceration are at highest risk of developing foot ulcers. Diabetes is not itself a significant risk factor as other comorbidities, such as neuropathy and peripheral arterial disease, have stronger associations with ulceration. These findings will help reduce the incidence of foot ulceration and its associated complications.
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**Additional file 1.** Complete dataset of participant characteristics according to foot ulceration status at follow-up. Table showing the complete dataset of participant characteristics according to foot ulceration status at follow-up. **Additional file 2.** Complete dataset of primary and secondary outcomes according to foot ulceration status at follow-up. Table showing the complete dataset of primary and secondary outcomes according to foot ulceration status at follow-up. **Additional file 3.** Foot examination, foot-health care behaviors and podiatry attendance according to foot ulceration status at follow-up. Table showing data relating to foot examination, foot-health care behaviors and podiatry attendance according to foot ulceration status at the 12-month follow-up. **Additional file 4.** Univariate Cox proportional hazard model of risk factors for foot ulceration stratified by diabetes status. Table showing the results of a Univariate Cox proportional hazard model of risk factors for foot ulceration stratified by diabetes status. **Additional file 5.** Kaplan-Meier survival estimates by (a) previous lower extremity amputation and (b) peripheral neuropathy. Figure showing Kaplan-Meier survival estimates by (a) previous lower extremity amputation and (b) peripheral neuropathy.

APD

:   Automated peritoneal dialysis

BMI

:   Body mass index

CAPD

:   Continuous ambulatory peritoneal dialysis

CI

:   Confidence interval

CRP

:   C-reactive protein

ESRD

:   End-stage renal disease

HbA1c

:   Glycated hemoglobin

HR

:   Hazard ratio

IQR

:   Interquartile range

MCS

:   Mental component score

MD

:   Mean difference

OR

:   Odds ratio

PAD

:   Peripheral arterial disease

PCS

:   Physical component score

PTH

:   Parathyroid hormone

RR

:   Relative risk

SD

:   Standard deviation

SF-36v2

:   Short-Form 36 version 2.0
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